Nanomedicine activation profile determines efficacy depending on tumor c-Myc expression
The half-life of a potent c-Myc inhibitor JQ1H was improved by encapsulating inside nanomicelles. Two types of nanomicelles were designed depending on the tumor acidity-driven activation; one is fast drug-releasing (FR-JQ1H/m), and another is slow releasing (SR-JQ1H/m). Anticancer activity study in mice revealed that FR-JQ1H/m was more effective in c-Myc high tumor, whereas SR-JQ1H/m was superior in c-Myc low tumor.
Comment at bottem of page